20/20 Biolabs, Inc. ·
AIDX 8-K 2026-08-05
20/20 Biolabs, Inc. (AIDX) 8-K dated 2026-08-05 — accession 0001213900-26-085514.
20/20 Biolabs, Inc. (AIDX) common stock.
20/20 Biolabs, Inc. filed a 8-K on 2026-08-05. Accession 0001213900-26-085514.
This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported AIDX revenue for 2025-12-31 was $2.0M. Net income was -$3.7M. Revenue was up 16.7% from 2024-12-31 to 2025-12-31.
Not investment advice. The AIDX SEC hub lists recent forms. The stock page is the research view.